COPEGUS Drug Patent Profile

Which patents cover Copegus, and when can generic versions of Copegus launch?

Copegus is a drug marketed by Roche and is included in one NDA.

The generic ingredient in COPEGUS is ribavirin. There are fifteen drug master file entries for this compound. Seven suppliers are listed for this compound. Additional details are available on the ribavirin profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Copegus

A generic version of COPEGUS was approved as ribavirin by ZYDUS PHARMS USA on October 28^th, 2005.

Summary for COPEGUS

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	160
DailyMed Link:	COPEGUS at DailyMed

Recent Clinical Trials for COPEGUS

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Weill Medical College of Cornell University	Early Phase 1
Memorial Sloan Kettering Cancer Center	Early Phase 1
M.D. Anderson Cancer Center	Phase 1/Phase 2

See all COPEGUS clinical trials

US Patents and Regulatory Information for COPEGUS

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Roche	COPEGUS	ribavirin	TABLET;ORAL	021511-001	Dec 3, 2002		DISCN	Yes	No
Roche	COPEGUS	ribavirin	TABLET;ORAL	021511-002	Jun 21, 2005		DISCN	Yes	No

EU/EMA Drug Approvals for COPEGUS

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Merck Sharp and Dohme B.V	Rebetol	ribavirin	EMEA/H/C/000246Rebetol is indicated in combination with other medicinal products for the treatment of chronic hepatitis C (CHC) in adults.Rebetol is indicated in combination with other medicinal products for the treatment of chronic hepatitis C (CHC) for paediatric patients (children 3 years of age and older and adolescents) not previously treated and without liver decompensation.	Withdrawn	no	no	no	1999-05-06
Teva B.V.	Ribavirin Teva Pharma B.V.	ribavirin	EMEA/H/C/001064Ribavirin Teva Pharma B.V. is indicated in combination with other medicinal products for the treatment ofchronic hepatitis C (CHC) in adults (see sections 4.2, 4.4, and 5.1).Ribavirin Teva Pharma B.V. is indicated in combination with other medicinal products for the treatment ofchronic hepatitis C (CHC) for paediatric patients (children 3 years of age and older and adolescents) notpreviously treated and without liver decompensation (see sections 4.2, 4.4 and 5.1).	Withdrawn	yes	no	no	2009-07-01
Teva B.V.	Ribavirin Teva	ribavirin	EMEA/H/C/001018Ribavirin Teva is indicated for the treatment of chronic hepatitis C virus (HCV) infection in adults, children 3 years of age and older and adolescents and must only be used as part of a combination regimen with interferon alfa-2b. Ribavirin monotherapy must not be used.There is no safety or efficacy information on the use of Ribavirin with other forms of interferon (i.e. not alfa-2b).Naïve patients Adult patients Ribavirin Teva is indicated, in combination with interferon alfa-2b, for the treatment of adult patients with all types of chronic hepatitis C except genotype 1, not previously treated, without liver decompensation, with elevated alanine aminotransferase (ALT), who are positive for hepatitis C viral ribonucleic acid HCV-RNA.Paediatric patients (children 3 years of age and older and adolescents) Ribavirin Teva is indicated, in a combination regimen with interferon alfa­2b, for the treatment of children and adolescents 3 years of age and older, who have all types of chronic hepatitis C except genotype 1, not previously treated, without liver decompensation, and who are positive for HCV-RNA.When deciding not to defer treatment until adulthood, it is important to consider that the combination therapy induced a growth inhibition that may be irreversible in some patients. The reversibility of growth inhibition is uncertain. The decision to treat should be made on a case by case basis.Previous treatment failure patientsAdult patients Ribavirin Teva is indicated, in combination with interferon alfa-2b, for the treatment of adult patients with chronic hepatitis C who have previously responded (with normalisation of ALT at the end of treatment) to interferon alpha monotherapy but who have subsequently relapsed.	Withdrawn	yes	no	no	2009-03-31

Market Dynamics and Financial Trajectory for COPEGUS (Ribavirin)

Last updated: March 9, 2026

What is COPEGUS and its current market status?

COPEGUS (Ribavirin) is an antiviral medication developed by Roche. It primarily treats chronic hepatitis C (HCV) as part of combination therapy with interferons. The drug was approved by the U.S. Food and Drug Administration (FDA) in 1998 and is marketed globally.

Market availability has diminished due to the advent of direct-acting antivirals (DAAs), which have replaced ribavirin in most treatment protocols owing to higher efficacy and better tolerability. Nonetheless, in some regions or specific patient populations, COPEGUS remains in use.

How has the market evolved for COPEGUS over the last decade?

The shift from ribavirin-based regimens to DAA regimens has eroded COPEGUS's market share substantially. The global HCV treatment landscape shifted around 2014-2016 following the approval and commercialization of drugs such as Sofosbuvir (Sovaldi) and Harvoni.

Key factors influencing the decline include:

• Efficacy: DAAs achieve sustained virological response (SVR) rates exceeding 90%, whereas ribavirin regimens typically achieve rates around 50-80% depending on patient genotype.
• Side Effects: Ribavirin causes hemolytic anemia and other adverse effects, leading to reduced use.
• Treatment Duration: DAA regimens shorten therapy duration from 24-48 weeks to 8-12 weeks.
• Cost Dynamics: Although DAAs are costly initially, price reductions and generic options have increased access, displacing ribavirin.

Regional market data:

Region	2012 Revenue (USD millions)	2020 Revenue (USD millions)	% Decline	Comments
Global	600	200	66.7%	Decline due to DAA dominance
U.S.	400	80	80%	Reduced prescribing, alternative DAA use
Europe	150	50	66.7%	Replacement by newer therapies

What are the financial outlooks for COPEGUS?

Market forecasts predict continued decline, but specific niche uses could maintain some revenue. Key aspects:

• Patent status: The original patent expired, enabling generics in many markets, intensifying price competition.
• Generic penetration: Countries like India, China, and Brazil produce generic ribavirin, reducing prices.
• Regulatory status: Some countries have restricted or revoked approvals as newer treatments dominate.

Revenue projections:

Year	Estimated Revenue (USD millions)	Commentary
2023	150	Market saturation continues decline, niche use persists
2025	100	Further decrease, especially outside developed markets
2030	30	Mostly obsolete, limited use in specific conditions

What factors influence the future trajectory?

• Generics and price erosion: Widespread generic manufacturing lowers prices.
• Regulatory shifts: Countries adopting newer treatments limit access to ribavirin.
• Clinical guidelines: Treatment protocols favor DAAs exclusively.
• Market reorganization: Consolidation of hepatitis C treatment into specialized centers reduces off-label ribavirin use.

How does COPEGUS compare with newer hepatitis C therapies?

Aspect	COPEGUS (Ribavirin)	DAAs (e.g., Sofosbuvir-based)
Efficacy	50-80% SVR (varies)	>90% SVR, higher across genotypes
Treatment duration	24-48 weeks	8-12 weeks
Side effects	Hemolytic anemia, fatigue	Mild or infrequent
Cost (initial)	Low (due to generics)	High, but decreasing
Market presence	Declining	Expanding or stable in niche

Key drivers impacting future sales

• Competitive pricing through generics.
• Policy shifts favoring DAA use exclusively.
• Limited patient populations with contraindications to DAAs.
• Potential for off-label or combination uses in rare cases.

Conclusion

The market for COPEGUS has contracted significantly since the rise of DAA therapies. It remains in use primarily for specific patient subsets or regions with limited access to newer medications. Revenue streams are expected to fall sharply over the next five years, approaching minimal levels by 2030.

Key Takeaways

• COPEGUS's global revenue declined over 66.7% from 2012 to 2020.
• The advent of DAAs has rendered ribavirin largely obsolete in hepatitis C treatment.
• Patent expiration and generics have driven prices down, further reducing revenues.
• Future use will mainly depend on regions with limited access to newer therapies.
• The drug's role is expected to diminish to niche applications within the next decade.

FAQs

1. Why has COPEGUS lost market share?
   DAAs provide higher efficacy, shorter treatment durations, and better safety profiles, displacing ribavirin.

2. Are there regions where COPEGUS is still relevant?
   In low-income countries or areas with limited healthcare infrastructure, generics may sustain minimal use.

3. What is the potential for COPEGUS in combination with newer treatments?
   Some research explores ribavirin as part of salvage or palliative regimens, but routine use is declining.

4. Will COPEGUS return to prominence?
   Unlikely, barring unforeseen developments or new indications, given current treatment standards.

5. How do generics impact COPEGUS's pricing?
   Generics have reduced prices by up to 80-90%, making the drug less profitable for original manufacturers.

---

References

[1] European Medicines Agency. (2014). Roche’s Copegus (ribavirin): Summary of product characteristics.
[2] U.S. Food and Drug Administration. (1998). FDA Approval of Ribavirin for Hepatitis C.
[3] MarketWatch. (2021). Hepatitis C drug market analysis.
[4] IMS Health. (2012-2020). Global pharmaceutical sales data.
[5] World Health Organization. (2022). Hepatitis C treatment guidelines.